Oncorus: Oncorus is the leader in next-generation oncolytic immunotherapies. The company's lead program is a Ph1 oHSV with complementary payloads to encourage immune stimulation (PD1, CCL4, IL12, FLT3, CTLA4). Secondary programs include synthetic viruses that do not need to be dosed intra-tumorally.
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Public, USA
Market Cap
100MM - 500MM
50 Hampshire Street
Suite 401
Cambridge, MA 02139
United States

Company Participants at Oncorus Synthetic Day June 2021

  • Ted Ashburn, CEO

Upcoming Company Event Participation

Top 10 Holders of Oncorus, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Deerfield Management Company LP 12.29 3,148,977 54.48 13F 3/31/21
MPM Asset Management LLC 11.12 2,849,464 49.30 13F 3/31/21
MPM Oncology Impact Management LP 9.28 2,377,031 41.12 13F 3/31/21
Perceptive Advisors LLC 7.77 1,989,987 34.43 13F 3/31/21
Citadel LP 7.39 1,893,035 32.75 13F 3/31/21
Citadel Advisors LLC 7.24 1,855,355 32.10 Stakes 3/30/21
CHI Advisors LLC 6.91 1,771,786 30.65 13F 3/31/21
Fosun International Ltd. 3.76 962,321 16.65 13F 3/31/21
Sphera Funds Management Ltd. 3.52 903,111 15.62 13F 3/31/21
The Vanguard Group, Inc. 1.84 472,259 8.17 Funds 4/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.